SCHEMBL4836656

SCHEMBL4836656

COP(=O)(Cc1ccc(NC(=O)/C=C/c2nnsc2-c2ccc(F)cc2)cc1)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
MMP1 P03956 4/20 0.38
MMP2 P08253 4/20 0.38
MMP9 P14780 4/20 0.38
EGFR P00533 1/20 0.38
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
CDK19 Q9BWU1 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
HPSE Q9Y251 2/20 0.37
TP53 P04637 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
SNCA P37840 2/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TDP1 Q9NUW8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4827010 0.91 BTK (0.40) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4829380 0.89 MMP1 (0.40) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4829396 0.89 MMP1 (0.40) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4831233 0.85 NPC1 (0.39) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4836532 0.79 MAOB (0.43) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4836682 0.79 MAOB (0.43) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4827004 0.79 MAOB (0.41) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4827021 0.79 MAOB (0.41) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL27632230 0.78 MAOB (0.44) NPC1RAB9ASMN1; SMN2LMNAMMP1
SCHEMBL4834265 0.77 BTK (0.40) NPC1RAB9ASMN1; SMN2LMNAMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 NPC1 1170/4885RAB9A 4059/4885SMN1; SMN2 75/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 NPC1 1170/4885RAB9A 4059/4885SMN1; SMN2 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.